Microbiota-Based Live Biotherapeutic Products for Clostridioides Difficile Infection- The Devil is in the Details

References

• Martin TC, Visconti A, Spector TD, et al. Conducting metagenomic studies in microbiology and clinical research. Appl Microbiol Biotechnol. 2018;102(20):8629–8646. doi:10.1007/s00253-018-9209-9
   PubMed Web of Science ®Google Scholar
• Integrative, HMP. The integrative human microbiome project. Nature. 2019;569(7758):641–648. doi:10.1038/s41586-019-1238-8
   PubMed Web of Science ®Google Scholar
• Oliveira RA, Pamer EG. Assembling symbiotic bacterial species into live therapeutic consortia that reconstitute microbiome functions. Cell Host Microbe. 2023;31(4):472–484. doi:10.1016/j.chom.2023.03.002
   PubMed Web of Science ®Google Scholar
• Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs. 2010;70(8):965–981. doi:10.2165/10898540-000000000-00000
   PubMed Web of Science ®Google Scholar
• Seres therapeutics announces strategic collaboration with nestlé health science for microbiome-based clostridium difficile and inflammatory bowel disease therapies in markets outside of north America. 2016.
   Google Scholar
• FDA approves first fecal microbiota product. 2022.
   Google Scholar
• Claro T, Widaa A, O’Seaghdha Met al. Staphylococcus aureus protein A binds to osteoblasts and triggers signals that weaken bone in osteomyelitis. PLoS One. 2011;6(4):e18748.
   PubMed Web of Science ®Google Scholar
• Wang R. Clostridioides difficile infection: microbe-microbe interactions and live biotherapeutics. Front Microbiol. 2023; 14:1182612.
   PubMed Web of Science ®Google Scholar
• O’Donnell MM, Hegarty JW, Healy B, et al. Identification of ADS024, a newly characterized strain of bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities. Sci Rep. 2022;12(1):9283. doi:10.1038/s41598-022-13248-4
   PubMed Web of Science ®Google Scholar
• Xie Y, Chupina Estrada A, Nelson B, et al. ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis. Front Microbiol. 2022;13:1072534. doi:10.3389/fmicb.2022.1072534
   PubMed Web of Science ®Google Scholar
• Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent clostridioides difficile infection. Drugs. 2022;82(15):1527–1538. doi:10.1007/s40265-022-01797-x
   PubMed Web of Science ®Google Scholar
• Khanna S, Pardi DS, Jones C, et al. RBX7455, a non-frozen, orally administered investigational live biotherapeutic, is safe, effective, and shifts patients’ microbiomes in a phase 1 study for recurrent clostridioides difficile infections. Clin Infect Dis. 2021;73(7):e1613–e1620. doi:10.1093/cid/ciaa1430
   PubMed Web of Science ®Google Scholar
• McGovern BH, Ford CB, Henn MR, et al. SER-109, an investigational microbiome drug to reduce recurrence after clostridioides difficile infection: lessons learned from a phase 2 trial. Clin Infect Dis. 2021;72(12):2132–2140. doi:10.1093/cid/ciaa387
   PubMed Web of Science ®Google Scholar
• Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent clostridioides difficile Infection. N Engl J Med. 2022;386(3):220–229. doi:10.1056/NEJMoa2106516
   PubMed Web of Science ®Google Scholar
• McChalicher C, Abdulaziz A, Zhou SS, et al. Manufacturing Process of SER-109, a purified investigational microbiome therapeutic, reduces risk of coronavirus transmission from donor stool. Open Forum Infect Dis. 2022;9(9):448. doi:10.1093/ofid/ofac448
   Web of Science ®Google Scholar
• Khanna S, et al. SER-109: an oral investigational microbiome therapeutic for patients with recurrent clostridioides difficile infection (rCDI). Antibiotics. 2022;11(9):1.
   Google Scholar
• Hota SS, Poutanen SM. Microbiome-Based Therapeutics for Clostridioides Difficile Infection: Helpful Solutions or Unclear Cocktails? Lancet Infect Dis; 2023.
   Google Scholar
• Murillo O, Roset A, Sobrino B, et al. Streptococcal vertebral osteomyelitis: multiple faces of the same disease. Clin Microbiol Infect. 2014;20(1):O33–8. doi:10.1111/1469-0691.12302
   PubMed Web of Science ®Google Scholar
• Gou HZ, Zhang Y-L, Ren L-F, et al. How do intestinal probiotics restore the intestinal barrier? Front Microbiol. 2022;13:929346. doi:10.3389/fmicb.2022.929346
   PubMed Web of Science ®Google Scholar
• Haran JP, McCormick BA. Aging, frailty, and the microbiome-How dysbiosis influences human aging and disease. Gastroenterology. 2021;160(2):507–523. doi:10.1053/j.gastro.2020.09.060
   PubMed Web of Science ®Google Scholar
• Mohan A, Godugu S, Joshi SS, et al. Gut-brain axis: altered microbiome and depression - review. Ann Med Surg Lond. 2023;85(5):1784–1789. doi:10.1097/MS9.0000000000000573
   PubMed Web of Science ®Google Scholar
• Seekatz AM, Safdar N, Khanna S. The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol. 2022;15:17562848221134396. doi:10.1177/17562848221134396
   Web of Science ®Google Scholar
• Dawkins JJ, Allegretti JR, Gibson TE, et al. Gut metabolites predict Clostridioides difficile recurrence. Microbiome. 2022;10(1):87. doi:10.1186/s40168-022-01284-1
   PubMed Web of Science ®Google Scholar
• Feuerstadt P, Nelson WW, Teigland C, et al. Clinical burden of recurrent clostridioides difficile infection in the medicare population: a real-world claims analysis. Anti Stewar Healthcare Epid. 2022;2(1):e60. doi:10.1017/ash.2022.2
   Google Scholar
• Davies K. Risk factors for primary clostridium difficile infection; results from the observational study of risk factors for clostridium difficile infection in hospitalized patients with infective diarrhea; 2020. 8.
   Google Scholar
• Tabak YP, Srinivasan A, Yu KC, et al. Hospital-level high-risk antibiotic use in relation to hospital-associated Clostridioides difficile infections: retrospective analysis of 2016–2017 data from US hospitals. Infect Control Hosp Epidemiol. 2019;40(11):1229–1235. doi:10.1017/ice.2019.236
   PubMed Web of Science ®Google Scholar
• Brown KA, Langford B, Schwartz KL, et al. Antibiotic prescribing choices and their comparative c. difficile infection risks: a longitudinal case-cohort study. Clinl Infect Dis. 2020;72(5):836–844. doi:10.1093/cid/ciaa124
   Web of Science ®Google Scholar
• Nagpal R, Mainali R, Ahmadi S, et al. Gut microbiome and aging: physiological and mechanistic insights. Nutr Healthy Aging. 2018;4(4):267–285. doi:10.3233/NHA-170030
   PubMedGoogle Scholar
• Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–748. doi:10.1136/gutjnl-2015-310376
   PubMed Web of Science ®Google Scholar
• Abt MC, McKenney PT, Pamer EG. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol. 2016;14(10):609–620. doi:10.1038/nrmicro.2016.108
   PubMed Web of Science ®Google Scholar
• Aguirre AM, Sorg JA. Gut associated metabolites and their roles in Clostridioides difficile pathogenesis. Gut Microbes. 2022;14(1):2094672. doi:10.1080/19490976.2022.2094672
   PubMed Web of Science ®Google Scholar
• Giel JL, Sorg JA, Sonenshein AL, et al. Metabolism of bile salts in mice influences spore germination in Clostridium difficile. PLoS One. 2010;5(1):e8740. doi:10.1371/journal.pone.0008740
   PubMed Web of Science ®Google Scholar
• Mullish BH, Allegretti JR. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol. 2021;14:17562848211017725. doi:10.1177/17562848211017725
   Web of Science ®Google Scholar
• Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008;190(7):2505–2512. doi:10.1128/JB.01765-07
   PubMed Web of Science ®Google Scholar
• Theriot CM, Koenigsknecht MJ, Carlson PE, et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat Commun. 2014;5(1):3114. doi:10.1038/ncomms4114
   PubMed Web of Science ®Google Scholar
• Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA): 2021 focused update guidelines on management of clostridioides difficile infection in adults. Clinl Infect Dis. 2021;73(5):e1029–e1044. doi:10.1093/cid/ciab549
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. New England J Med. 2017;376(4):305–317. doi:10.1056/NEJMoa1602615
   PubMed Web of Science ®Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile Infection in the United States. New England J med. 2015;372(9):825–834. doi:10.1056/NEJMoa1408913
   PubMed Web of Science ®Google Scholar
• Leong C, Zelenitsky S. Treatment strategies for recurrent clostridium difficile infection. Can J Hosp Pharm. 2013;66(6):361–368. doi:10.4212/cjhp.v66i6.1301
   PubMedGoogle Scholar
• Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;2(Suppl 2):S154–61. doi:10.1093/cid/cis462
   Google Scholar
• Feuerstadt P, Boules M, Stong L, et al. Clinical complications in patients with primary and recurrent Clostridioides difficile infection: a real-world data analysis. SAGE Open Med. 2021;9:2050312120986733. doi:10.1177/2050312120986733
   Web of Science ®Google Scholar
• Hall JF, Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am J Surg. 2008;196(3):384–388. doi:10.1016/j.amjsurg.2007.11.017
   PubMed Web of Science ®Google Scholar
• Lurienne L, Bandinelli P-A, Galvain T, et al. Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey. J Patient Rep Outcomes. 2020;4(1):14. doi:10.1186/s41687-020-0179-1
   PubMedGoogle Scholar
• Guillemin I, Marrel A, Lambert J, et al. Patients’ experience and perception of hospital-treated Clostridium difficile infections: a qualitative study. Patient. 2014;7(1):97–105. doi:10.1007/s40271-013-0043-y
   PubMedGoogle Scholar
• Reveles KR, Yang M, Garcia-Horton V, et al. Economic impact of recurrent clostridioides difficile infection in the USA: a systematic literature review and cost synthesis. Adv Ther. 2023;40(7):3104–3134. doi:10.1007/s12325-023-02498-x
   PubMed Web of Science ®Google Scholar
• Wells M. Self as historical artifact: ge Hong and early Chinese autobiographical writing. Early Med China. 2003;2003(1):71–103. doi:10.1179/152991003788138465
   Google Scholar
• Stripling J, Rodriguez M. Current evidence in delivery and therapeutic uses of fecal microbiota transplantation in human diseases-clostridium difficile disease and beyond. Am J Med Sci. 2018;356(5):424–432. doi:10.1016/j.amjms.2018.08.010
   PubMed Web of Science ®Google Scholar
• de Groot PF, Frissen MN, de Clercq NC, et al. Fecal microbiota transplantation in metabolic syndrome: history, present and future. Gut Microbes. 2017;8(3):253–267. doi:10.1080/19490976.2017.1293224
   PubMed Web of Science ®Google Scholar
• Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44(5):854–859.
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Moon N, Chang TW, et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978;75(5):778–782. doi:10.1016/0016-5085(78)90457-2
   PubMed Web of Science ®Google Scholar
• George WL, Goldstein EC, Sutter V, et al. Aetiology of antimicrobial-agent-associated colitis. Lancet. 1978;1(8068):802–803. doi:10.1016/S0140-6736(78)93001-5
   PubMed Web of Science ®Google Scholar
• Giancola SE, Williams RJ, Gentry CA. Prevalence of the clostridium difficile bi/nap1/027 strain across the United States veterans health administration. Clin Microbiol Infect. 2018;24(8):877–881. doi:10.1016/j.cmi.2017.11.011
   PubMed Web of Science ®Google Scholar
• Prevention CJTR. Antibiotic resistance threats in the United States, 2013; 2013;50–52.
   Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent clostridium difficile. New England J med. 2013;368(5):407–415. doi:10.1056/NEJMoa1205037
   PubMed Web of Science ®Google Scholar
• Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection. 2012;40(6):643–648. doi:10.1007/s15010-012-0307-9
   PubMed Web of Science ®Google Scholar
• Schwan A. Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet. 1983;2(8354):845. doi:10.1016/S0140-6736(83)90753-5
   PubMed Web of Science ®Google Scholar
• Allegretti JR, Fischer M, Sagi SV, et al. Fecal microbiota transplantation capsules with targeted colonic versus gastric delivery in recurrent clostridium difficile infection: a comparative cohort analysis of high and Lose dose. Dig Dis Sci. 2019;64(6):1672–1678. doi:10.1007/s10620-018-5396-6
   PubMed Web of Science ®Google Scholar
• Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36(5):580–585. doi:10.1086/367657
   PubMed Web of Science ®Google Scholar
• Woodworth MH, Carpentieri C, Sitchenko KL, et al. Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review. Gut Microbes. 2017;8(3):225–237. doi:10.1080/19490976.2017.1286006
   PubMed Web of Science ®Google Scholar
• Khoruts A. Fecal microbiota transplantation-early steps on a long journey ahead. Gut Microbes. 2017;8(3):199–204. doi:10.1080/19490976.2017.1316447
   PubMed Web of Science ®Google Scholar
• Koopman N, van Leeuwen P, Brul S, et al. History of fecal transplantation; camel feces contains limited amounts of Bacillus subtilis spores and likely has no traditional role in the treatment of dysentery. PLoS One. 2022;17(8):e0272607. doi:10.1371/journal.pone.0272607
   PubMed Web of Science ®Google Scholar
• Relman D, Rustgi A, Vender R. Joint Society letter to FDA—Current consensus guidance on donor screening and stool testing for FMT; 2013.
   Google Scholar
• Kelly CR, Kunde SS, Khoruts A. Guidance on preparing an investigational new drug application for fecal microbiota transplantation studies. Clin Gastroenterol Hepatol. 2014;12(2):283–288. doi:10.1016/j.cgh.2013.09.060
   PubMed Web of Science ®Google Scholar
• Hota SS. Regional variability in fecal microbiota transplantation practices: a survey of the southern Ontario fecal microbiota transplantation movement. Can Med Assoc J. 2018;6(2):E184–E190.
   Google Scholar
• Panchal P, Budree S, Scheeler A, et al. Scaling safe access to fecal microbiota transplantation: past, present, and future. Curr Gastroenterol Rep. 2018;20(4):14. doi:10.1007/s11894-018-0619-8
   PubMedGoogle Scholar
• Chen J, et al. Stool banking for fecal microbiota transplantation: methods and operations at a large stool bank. Front Cell Infect Microbiol. 2021;11:622949.
   PubMed Web of Science ®Google Scholar
• OpenBiome Product Order Form. Available from: https://openbiome.org/wp-content/uploads/Order-Form_August-2023.pdf. AccessedFebruary 12, 2024.
   Google Scholar
• Hota SS, Poutanen SM. Microbiome-based therapeutics for Clostridioides difficile infection: helpful solutions or unclear cocktails? Lancet Infect Dis. 2023;23(9):999–1000. doi:10.1016/S1473-3099(23)00484-X
   PubMed Web of Science ®Google Scholar
• Sandhu A, Chopra T. Fecal microbiota transplantation for recurrent Clostridioides difficile, safety, and pitfalls. Therap Adv Gastroenterol. 2021;14:17562848211053105. doi:10.1177/17562848211053105
   Web of Science ®Google Scholar
• Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol. 2013;108(4):500–508. doi:10.1038/ajg.2013.59
   PubMed Web of Science ®Google Scholar
• Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection: a randomized trial. Annals of Internal Medicine. 2016;165(9):609–616. doi:10.7326/M16-0271
   PubMed Web of Science ®Google Scholar
• Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis. 2017;64(3):265–271. doi:10.1093/cid/ciw731
   PubMed Web of Science ®Google Scholar
• Tariq R, Pardi DS, Bartlett MG, et al. Low Cure rates in controlled trials of fecal microbiota transplantation for recurrent clostridium difficile infection: a systematic review and meta-analysis. Clin Infect Dis. 2019;68(8):1351–1358. doi:10.1093/cid/ciy721
   PubMed Web of Science ®Google Scholar
• Song YN. Fecal microbiota transplantation for severe or fulminant clostridioides difficile infection. Systematic Review and Meta-Analysis J Can Assoc. 2022;5(1):e1–e11.
   Google Scholar
• Quera R, Espinoza R, Estay C, et al. Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn’s disease and recurrent Clostridium difficile infection. J Crohns Colitis. 2014;8(3):252–253. doi:10.1016/j.crohns.2013.10.002
   PubMed Web of Science ®Google Scholar
• Trubiano JA, Gardiner B, Kwong JC, et al. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol. 2013;25(2):255–257. doi:10.1097/MEG.0b013e32835b2da9
   PubMed Web of Science ®Google Scholar
• Solari PR, Fairchild PG, Noa LJ, et al. Tempered enthusiasm for fecal transplant. Clin Infect Dis. 2014;59(2):319. doi:10.1093/cid/ciu278
   PubMed Web of Science ®Google Scholar
• Baxter M, Ahmad T, Colville A, et al. Fatal aspiration pneumonia as a complication of fecal microbiota transplant. Clin Infect Dis. 2015;61(1):136–137. doi:10.1093/cid/civ247
   PubMed Web of Science ®Google Scholar
• Roberts MJ, Parambi A, Barrett L, et al. Multifocal abscesses due to multiresistant Escherichia coli after transrectal ultrasound-guided prostate biopsy. Med J Aust. 2013;198(5):282–284. doi:10.5694/mja12.11719
   PubMed Web of Science ®Google Scholar
• DeFilipp Z, Bloom PP, Torres Soto M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381(21):2043–2050. doi:10.1056/NEJMoa1910437
   PubMed Web of Science ®Google Scholar
• Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to monkeypox Virus. 2022.
   Google Scholar
• Ekekezie C, Perler BK, Wexler A, et al. Understanding the scope of do-it-yourself fecal microbiota transplant. Am J Gastroenterol. 2020;115(4):603–607. doi:10.14309/ajg.0000000000000499
   PubMed Web of Science ®Google Scholar
• Browne HP, Neville BA, Forster SC, et al. Transmission of the gut microbiota: spreading of health. Nat Rev Microbiol. 2017;15(9):531–543. doi:10.1038/nrmicro.2017.50
   PubMed Web of Science ®Google Scholar
• Halaweish HF, Boatman S, Staley C. Encapsulated fecal microbiota transplantation: development, efficacy, and clinical application. Front Cell Infect Microbiol. 2022;12:826114. doi:10.3389/fcimb.2022.826114
   PubMed Web of Science ®Google Scholar
• Khoruts A, Kabaga A. Investigator’s brochure, fecal microbiota; mtp-101-lf. Program UMTEditor;.2022;22.
   Google Scholar
• Jiang ZD, Jenq RR, Ajami NJ, et al. Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: a randomized clinical trial. PLoS One. 2018;13(11):e0205064. doi:10.1371/journal.pone.0205064
   PubMed Web of Science ®Google Scholar
• Kao D, Roach B, Silva M, et al. Effect of oral capsule– vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection. JAMA. 2017;318(20):1985–1993. doi:10.1001/jama.2017.17077
   PubMed Web of Science ®Google Scholar
• Ramai D, Zakhia K, Fields PJ, et al. Fecal Microbiota Transplantation (FMT) with colonoscopy is superior to enema and nasogastric tube while comparable to capsule for the treatment of recurrent clostridioides difficile infection: a systematic review and meta-analysis. Dig Dis Sci. 2021;66(2):369–380. doi:10.1007/s10620-020-06185-7
   PubMed Web of Science ®Google Scholar
• Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing clostridium difficile Infection. JAMA. 2014;312(17):1772–1778. doi:10.1001/jama.2014.13875
   PubMed Web of Science ®Google Scholar
• McChalicher CW, Auniņš JG. Drugging the microbiome and bacterial live biotherapeutic consortium production. Curr Opin Biotechnol. 2022;78:102801. doi:10.1016/j.copbio.2022.102801
   PubMed Web of Science ®Google Scholar
• McChalicher CWJ, Lombardo M-J, Khanna S, et al. Manufacturing processes of a purified microbiome therapeutic reduce risk of transmission of potential bacterial pathogens in donor stool. J Infect Dis. 2023;228(10):1452–1455. doi:10.1093/infdis/jiad298
   PubMed Web of Science ®Google Scholar
• Qiu K, Anselmo AC. Batch culture formulation of live biotherapeutic products. Adv Ther. 2021;4(2). doi:10.1002/adtp.202000226
   Google Scholar
• Kao D, Wong K, Franz R, et al. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial. Lancet Gastroenterol Hepatol. 2021;6(4):282–291. doi:10.1016/S2468-1253(21)00007-8
   PubMed Web of Science ®Google Scholar
• Khanna S. S131 CP101, an investigational orally administered microbiome therapeutic, increases intestinal microbiome diversity and prevents recurrent c. difficile infection: results from a randomized, placebo-controlled trial. Am J Gastroenterol. 2021;116:S57.
   PubMed Web of Science ®Google Scholar
• Argemi X, Prévost G, Riegel P, et al. VISLISI trial, a prospective clinical study allowing identification of a new metalloprotease and putative virulence factor from Staphylococcus lugdunensis. Clin Microbiol Infect. 2017;23(5):334.e1–334.e8. doi:10.1016/j.cmi.2016.12.018
   PubMed Web of Science ®Google Scholar
• Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™ (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI; Available from: https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-and-nestle-health-science-announce-fda.Accessed June 01, 2023.
   Google Scholar
• Assimacopoulos A, Johnston B, Clabots C, et al. Post-prostate biopsy infection with Escherichia coli ST131 leading to epididymo-orchitis and meningitis caused by Gram-negative bacilli. J Clin Microbiol. 2012;50(12):4157–4159. doi:10.1128/JCM.02026-12
   PubMed Web of Science ®Google Scholar
• Fantoni M, Rossi TE, Rossi B, et al. Epidemiological and clinical features of pyogenic spondylodiscitis.. Eur Rev Med Pharmacol Sci. 2012;16:2–7.
   PubMed Web of Science ®Google Scholar
• Jr A,Late breaking abstract: an investigational oral microbiome drug, cp101, for the prevention of recurrent clostridioides difficile infection: a randomized, placebo-controlled, multi-center trial (prism3). Uni Eur Gastro J, 2021. 8(10): p. 1270–1271
   Google Scholar
• Hamilton MJ, Sadowski KA, Staley MJ; Compositions and methods for C. difficile Treatment. Regent of the University of Minnesota; Available fromhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10849936. Accessed June 23, 2020.
   Google Scholar
• News release: finch therapeutics announces decision to discontinue phase 3 trial of cp101 and focus on realizing the value of its intellectual property estate and other assets. 2023.
   Google Scholar
• Blaser MJ. Fecal microbiota transplantation for dysbiosis - predictable risks. N Engl J Med. 2019;381(21):2064–2066. doi:10.1056/NEJMe1913807
   PubMed Web of Science ®Google Scholar
• Dsouza M, Menon R, Crossette E, et al. Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. Cell Host Microbe. 2022;30(4):583–598.e8. doi:10.1016/j.chom.2022.03.016
   PubMed Web of Science ®Google Scholar
• Louie T, Golan Y, Khanna S, et al. VE303, a defined bacterial consortium, for prevention of recurrent clostridioides difficile infection. JAMA. 2023;329(16):1356–1366. doi:10.1001/jama.2023.4314
   PubMed Web of Science ®Google Scholar
• Villano SA, Seiberling M, Tatarowicz W, et al. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob Agents Chem. 2012;56(10):5224–5229. doi:10.1128/AAC.00913-12
   PubMed Web of Science ®Google Scholar
• Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic clostridium difficile strain m3 for prevention of recurrent c difficile infection. JAMA. 2015;313(17):1719–1727. doi:10.1001/jama.2015.3725
   PubMed Web of Science ®Google Scholar
• Brouwer MS. Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. Nat Commun, 2013. 4: p. 2601.
   PubMed Web of Science ®Google Scholar
• Sambol SP, Johnson S, Cheknis A, et al. Absence of toxin gene transfer from Clostridioides difficile strain 630Δerm to nontoxigenic C. difficile strain NTCD-M3r in filter mating experiments. PLoS One. 2022;17(6):e0270119. doi:10.1371/journal.pone.0270119
   PubMed Web of Science ®Google Scholar
• Takeda enters into strategic collaboration with nubiyota for microbiome therapeutics. 2017.
   Google Scholar
• NuBiyota MET Pipeline 2021 Available from: https://nubiyota.com/pipeline/.Accessed June 23, 2024.
   Google Scholar
• Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome. 2013;1(1):3. doi:10.1186/2049-2618-1-3
   PubMed Web of Science ®Google Scholar
• Morningside ventures launches adiso therapeutics to advance novel therapies for inflammatory diseases. 2022.
   Google Scholar
• Therapeutics A Portfolio of single strain live biotherapeutic products (SS-LBP) 2023. Available from: https://adisotx.com/science-and-pipeline/#pipeline. AccessedMarch 23, 2023.
   Google Scholar
• Alshrari AS, Hudu SA, Elmigdadi F, et al. The urgent threat of clostridioides difficile infection: a glimpse of the drugs of the future, with related patents and prospects. Biomedicines. 2023;11(2):426. doi:10.3390/biomedicines11020426
   PubMed Web of Science ®Google Scholar
• Farquhar RC, Hill L, Ross C, et al. Edible Products Comprising BacterialStrains and Methods of Use. P. Patent, Editor; 2021.
   Google Scholar
• Farquhar RM, Hill CK, Ross C, Rea P, O’Donnell M. Methods and Compositions for the Treatment of C. Difficile. U.S. Patent, Editor; 2022.
   Google Scholar
• Fromm M. DIFPROTEC - Trademark Details. Denmark; 2021.
   Google Scholar
• Khanna S, Sims M, Louie TJ, et al. SER-109: an oral investigational microbiome therapeutic for patients with recurrent clostridioides difficile infection (rCDI). Antibiotics. 2022;11(9):doi:10.3390/antibiotics11091234
   Google Scholar
• Jr A, Louie KC, Fisher T, et al. Late breaking abstract: an investigational oral microbiome drug, CP101, for the prevention of recurrent clostridioides difficile infection: a randomized, placebo-controlled, multi-center trial (PRISM3). Uni Eur Gastro J. 2021;8(10):1270–1271.
   Google Scholar
• Pharma D NTCD-M3 Phase 3 Design – Agreed with FDA and EMA, Partnership with Sebela Pharmaceuticals. 2023 Available from: https://www.destinypharma.com/pipeline/ntcd-m3/.AccessedSeptember 01, 2023.
   Google Scholar
• Ford C, Litcofsky K, McGovern B, et al. Engraftment of Investigational microbiome drug, SER-262, in subjects receiving vancomycin is associated with reduced rates of recurrence after primary clostridium difficile infection (CDI). Open Forum Infect Diseases. 2019;6(Supplement_2):S547–S548. doi:10.1093/ofid/ofz360.1367
   Google Scholar
• BiomeBank Submits for Market Authorisation of World First Microbial Therapy. 2021 Available from: https://www.biomebank.com/news/media-release/market-authorisation-of-world-first-microbial-therapy/.AccessedSeptember 17, 2023.
   Google Scholar
• Orenstein R, Dubberke E, Hardi R, et al. Safety and durability of RBX2660 (microbiota suspension) for recurrent clostridium difficile infection: results of the punch cd study. Clin Infect Dis. 2016;62(5):596–602. doi:10.1093/cid/civ938
   PubMed Web of Science ®Google Scholar
• Orenstein R, Dubberke ER, Khanna S, et al. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis. 2022;22(1):245. doi:10.1186/s12879-022-07256-y
   PubMed Web of Science ®Google Scholar
• Orenstein R. The role of microbiome-based therapeutics in clostridioides difficile infection: durable, long-term results of RBX2660. Infect Dis Ther. 2023;12(1):1–7. doi:10.1007/s40121-022-00714-9
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Orenstein R, Khanna S, et al. final results from a phase 2b randomized, placebo-controlled clinical Trial of RBX2660: a microbiota-based drug for the prevention of recurrent clostridioides difficile infection. Infect Dis Ther. 2023;12(2):703–709. doi:10.1007/s40121-022-00744-3
   PubMed Web of Science ®Google Scholar
• Lee C, Louie T, Bancke L, et al. Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therap Adv Gastroenterol. 2023;16:17562848231174277. doi:10.1177/17562848231174277
   Web of Science ®Google Scholar
• Garey KW, Dubberke ER, Guo A, et al. Effect of fecal microbiota, live-jslm (REBYOTA [RBL]) on health-related quality of life in patients with recurrent clostridioides difficile infection: results from the punch cd3 clinical trial. Open Forum Infect Dis. 2023;10(8):383. doi:10.1093/ofid/ofad383
   Web of Science ®Google Scholar
• Koo HL, Van JN, Zhao M, et al.Real-time polymerase chain reaction detection of asymptomatic clostridium difficile colonization and rising c. difficile –associated disease rates. Infect Control Hosp Epidemiol. 2014;35(6):667–673.doi:10.1086/676433
   PubMed Web of Science ®Google Scholar
• Feuerstadt P, Bancke HA. Abstract P2217: RBX2660, an investigational live microbiota-based biotherapeutic, improves outcomes of Clostridioides difficile infection in a real-world population: a retrospective study of use under enforcement discretion. In:American College of Gastroenterology (ACG 2021) Annual Meeting. 2021. Las Vegas, NV;2024.
   Google Scholar
• Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent clostridium difficile infection. J Infect Dis. 2016;214(2):173–181. doi:10.1093/infdis/jiv766
   PubMed Web of Science ®Google Scholar
• Sims MD, Khanna S, Feuerstadt P, et al. Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent clostridioides difficile infection. JAMA Network Open. 2023;6(2):e2255758–e2255758. doi:10.1001/jamanetworkopen.2022.55758
   PubMed Web of Science ®Google Scholar
• Cohen SH, Louie TJ, Sims M, et al. Extended follow-up of microbiome therapeutic SER-109 through 24 weeks for recurrent clostridioides difficile infection in a randomized clinical trial. JAMA. 2022;328(20):2062–2064. doi:10.1001/jama.2022.16476
   PubMed Web of Science ®Google Scholar
• Therapeutics S Expanded Access Program. Available from: https://www.serestherapeutics.com/patients-and-physicians/Expanded_Access.pdf.Accessed 2023 June 20, 2023.
   Google Scholar
• Feuerstadt P. Patient perception of route of rectal administration of live biotherapeutic product for recurrent clostridioides difficile infection. Patient Prefer Adherence, 2023. 17:2153–2159.
   PubMed Web of Science ®Google Scholar
• Jain N, Umar TP, Fahner A-F, et al. Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications. Gut Microbes. 2023;15(1):2232137. doi:10.1080/19490976.2023.2232137
   PubMed Web of Science ®Google Scholar
• Lodise T, Guo A, Yang M, et al. Budget impact analysis of REBYOTA™ (fecal microbiota, live-jslm [fmbl]) for preventing recurrent clostridioides difficile infection in the US. Adv Ther. 2023;40(6):2801–2819. doi:10.1007/s12325-023-02506-0
   PubMed Web of Science ®Google Scholar
• Bainum TB, Reveles KR, Hall RG, et al. Controversies in the prevention and treatment of clostridioides difficile infection in adults: a narrative review. Microorganisms. 2023;11(2):387. doi:10.3390/microorganisms11020387
   PubMed Web of Science ®Google Scholar
• Mohamed MFH. Efficacy, safety, and cost-effectiveness of bezlotoxumab in preventing recurrent clostridioides difficile infection. J Clin Gastro. 2023;2023:1.
   Google Scholar
• Vazquez Roque M. RBX7455 Before Surgery for the Treatment of Operable Breast Cancer. Mayo Clinic; 2023.
   Google Scholar
• Bloom P. VE303 for Treatment of Hepatic Encephalopathy (HE); 2021.
   Google Scholar
• Garfield M. VE202 in Patients with Mild-to-Moderate Ulcerative Colitis. Clinicaltrials.gov; 2023.
   Google Scholar
• Tejura B. A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT. clinicaltrials.gov;2021.
   Google Scholar
• Horvath A, Zukauskaite K, Hazia O, et al. Human gut microbiome: therapeutic opportunities for metabolic syndrome-Hype or hope? Endocrinol Diabetes Metab. 2023;7(1):e436. doi:10.1002/edm2.436
   PubMedGoogle Scholar